Teza Capital Management LLC Raises Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Teza Capital Management LLC boosted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 20.4% during the fourth quarter, Holdings Channel.com reports. The firm owned 5,857 shares of the biopharmaceutical company’s stock after acquiring an additional 993 shares during the quarter. Teza Capital Management LLC’s holdings in Ultragenyx Pharmaceutical were worth $246,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Deep Track Capital LP bought a new stake in shares of Ultragenyx Pharmaceutical in the 4th quarter worth approximately $27,493,000. KBC Group NV raised its stake in Ultragenyx Pharmaceutical by 2,275.8% during the fourth quarter. KBC Group NV now owns 61,010 shares of the biopharmaceutical company’s stock valued at $2,567,000 after buying an additional 58,442 shares during the last quarter. Dark Forest Capital Management LP bought a new stake in Ultragenyx Pharmaceutical in the fourth quarter worth $459,000. First Light Asset Management LLC grew its stake in shares of Ultragenyx Pharmaceutical by 1.1% in the fourth quarter. First Light Asset Management LLC now owns 763,607 shares of the biopharmaceutical company’s stock worth $32,125,000 after acquiring an additional 8,505 shares during the last quarter. Finally, abrdn plc increased its holdings in shares of Ultragenyx Pharmaceutical by 25.2% during the fourth quarter. abrdn plc now owns 317,125 shares of the biopharmaceutical company’s stock valued at $13,341,000 after acquiring an additional 63,821 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

Analysts Set New Price Targets

RARE has been the topic of a number of analyst reports. Morgan Stanley upped their price target on shares of Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the stock an “overweight” rating in a research note on Friday, May 9th. HC Wainwright reaffirmed a “buy” rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. JPMorgan Chase & Co. increased their price target on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an “overweight” rating in a report on Thursday, March 27th. Canaccord Genuity Group boosted their price objective on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a report on Tuesday, February 18th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $90.93.

Ultragenyx Pharmaceutical Trading Up 3.2%

Shares of RARE opened at $37.35 on Wednesday. The firm has a fifty day simple moving average of $36.27 and a two-hundred day simple moving average of $41.50. The firm has a market cap of $3.53 billion, a PE ratio of -5.89 and a beta of 0.34. Ultragenyx Pharmaceutical Inc. has a 1-year low of $29.59 and a 1-year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The firm had revenue of $139.29 million during the quarter, compared to analysts’ expectations of $145.98 million. During the same period in the previous year, the business posted ($2.03) earnings per share. The company’s revenue for the quarter was up 28.0% on a year-over-year basis. As a group, research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider John Richard Pinion sold 14,439 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $607,881.90. Following the completion of the sale, the insider now directly owns 107,766 shares of the company’s stock, valued at approximately $4,536,948.60. This represents a 11.82% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Thomas Richard Kassberg sold 6,028 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $253,778.80. Following the completion of the sale, the executive vice president now directly owns 265,238 shares of the company’s stock, valued at approximately $11,166,519.80. This trade represents a 2.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 125,405 shares of company stock valued at $5,285,169. 5.50% of the stock is owned by insiders.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.